

# Ekso Bionics® EksoZeroG Technology Named to Industry Hot List

RICHMOND, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, announced that its EksoZeroG industrial solution has been named to the industry recognized Hot List 2017. EksoZeroG was selected by Rental Management magazine from a record number of submissions as one of nearly 200 new products or services to be featured at The Rental Show® this year.

The EksoZeroG, a lightweight assistive device for industrial workers, is designed to bear the load of heavy tools and enhance both safety and productivity at construction sites. Produced by Ekso Works, the industrial division of Ekso Bionics, the EksoZeroG device easily mounts to aerial work platform rails and/or scaffolding and can hold a wide range of heavy construction tools, such as rotary hammers and pneumatic chipping guns.

The Ekso Works product line addresses some of the biggest challenges facing industrial workers: protecting workers and allowing them to finish jobs on time and within budget. With Ekso Bionics' industrial solutions, workers can complete tasks using heavy tools with less fatigue, better workmanship, and fewer workplace injuries.

Ekso Bionics will take part in two upcoming industrial trade shows to offer hands-on demonstrations of the EksoZeroG technology:

- The Rental Show  
February 26-March 1, 2017 in Orlando, Florida  
- Demonstrations: Booth #2774
- CONEXPO-CON/AGG  
March 7-11, 2017 in Las Vegas, Nevada  
- Demonstrations: Tech Experience – Silver Lot 3  
- Presentation: “Bionic Workers in Construction” by Russ Angold, co-founder and chief technology officer of Ekso Bionics  
March 9<sup>th</sup> at 1:15PM, Tech Talk Pavilion in Tech Experience area

## **About Ekso Bionics®**

Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: [www.eksobionics.com](http://www.eksobionics.com).

## **Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company's finalization of its financial statements for and as of the period and year ended December 31, 2016, information or new changes in facts or circumstances that may occur prior to the filing of the Company's Annual Report on Form 10-K that are required to be included therein, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at [www.eksobionics.com](http://www.eksobionics.com). The Company does not undertake to update these forward-looking statements.

### Media Contact:

Carrie Yamond/Rajni Dhanjani  
212-867-1788  
[cyamond@lazarpartners.com](mailto:cyamond@lazarpartners.com)

### Investor Contact:

Debbie Kaster  
415-937-5403  
[investors@eksobionics.com](mailto:investors@eksobionics.com)



Source: Ekso Bionics